U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07949448) titled 'Chimeric Antigen-Receptor-Modified T Cells Targeting B7-H3' on Nov. 13.
Brief Summary: LCCC 2534-ATL is an early-stage (Phase 1), single-center clinical study evaluating the safety of CAR T-cell therapy in children and adults with high-grade gliomas (HGGs), which are aggressive brain cancers.
The treatment, called iC9-CAR.B7-H3 T cells, uses modified immune cells designed to recognize and attack cancer cells with a protein called B7-H3. The treatment also includes a safety switch (iC9) designed to help stop the modified cells if serious side effects occur.
Earlier studies of B7-H3-targeted CAR T-cell therapy have shown encouraging...